Eckschlager C, Schwenoha K, Roth C, Bogner B, Oostingh GJ. Comparative analysis of high CRP-levels in human blood using point-of-care and laboratory-based methods.
Pract Lab Med 2019;
17:e00137. [PMID:
31649989 PMCID:
PMC6804588 DOI:
10.1016/j.plabm.2019.e00137]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Revised: 08/14/2019] [Accepted: 09/17/2019] [Indexed: 02/03/2023] Open
Abstract
Objectives
The use of point-of-care (POC) methods and the measurements of C-reactive protein (CRP) as a diagnostic marker have both increased over the past years. This has led to an increase in POC-methods analysing CRP. High CRP levels are often seen as an indication for the subscription of antibiotics. The quality of POC-systems compared to routine diagnostic measurements for the analysis of CRP is thereby of main importance, since many small practises will use POC-methods. This study compared high-level CRP concentrations (above 100 mg/L) using an i-CHROMATM with 2 routinely used laboratory-based systems (Architect and ABX).
Design
and Methods: A total of 199 patient samples with a CRP concentration above 100 mg/L were analysed with the i-CHROMATM POC system and the turbidimetric routine methods using the Architect and ABX equipment.
Results
The results of the i-CHROMATM device showed a significant decrease in the CRP levels compared to those obtained with the Architect and the ABX (i-CHROMATM vs. Architect: y = 0.6792x + 94.701; R2 = 0.4980, i-CHROMATM vs. ABX: y = 0.3674x + 118.05; R2 = 0.3964, Architect vs. ABX: y = 0.7657x + 36.337; R2 = 0.9311). Furthermore, data analysis showed a partition of the i-CHROMATM measurements in two defined clouds, which could not be explained with any of the available sample information.
Conclusions
This analysis showed the limitations of the i-CHROMATM CRP analyser. In addition, it illustrates the need for strict regulations on the information and output provided by companies regarding the boundaries of novel and existing diagnostic methods.
Collapse